Immunopathology of Loeys-Dietz Syndrome

Loeys-Dietz Syndrome Clinical Trial

— I-LoDiS  

Official title:

Immunopathology of Loeys-Dietz Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05472519
• Other study ID #: 69HCL22_0016
• Status: Completed
• Phase: N/A
• Start date: October 17, 2022
• Est. completion date: June 7, 2023

Study information

• Verified date: June 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Loeys-Dietz syndrome (LDS) is a rare vascular genetic disorder (estimated prevalence 1/25,000-1/100,000) due primarily to mutations in the Transforming growth factor beta (TGF-β) cytokine receptor 1 and 2 genes. In addition to a common vascular phenotype with Marfan syndrome (dilatation of the ascending aorta, arachnodactyly, lens dislocation), patients present specific malformations (bifid uvula, hypertelorism, tortuous arteries) and immuno-allergic manifestations (asthma, eczema, food allergy, eosinophilic esophagitis, chronic inflammatory bowel disease). Pathophysiologically, LDS appears to be associated with hyperactivation of the intracellular TGF-β signaling pathway in a manner similar to Marfan syndrome, as evidenced by increased intracellular phosphorylated Smad2/3 (pSmad2/3) in lymphocytes. The immuno-allergic complications appear paradoxical because of the major immunosuppressive role of this cytokine on lymphoid and myeloid immune lineages. The biological description of immunological abnormalities associated with LDS is based on a single 2013 study that found increased regulatory T (Treg) and Th2 lymphocyte polarizations, as well as increased circulating eosinophil and total IgE levels. In order to better understand the underlying mechanisms, the investigators propose to perform a descriptive clinical-biological study to identify and study the immune subpopulations most impacted by the causative mutations of LDS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: June 7, 2023
• Est. primary completion date: June 7, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 5 Years to 86 Years

Eligibility

Inclusion Criteria:

For patients with Loeys-Dietz syndrome:

• Patients aged = 5 years with Loeys-Dietz syndrome with a diagnosis confirmed by the presence of a TGF-ßR 1 or R2 mutation known to be pathogenic to patients.
• Free, informed and signed consent from the patient or both parents or legal guardians for minor patients.
• Patient affiliated to a social security system or similar.

For healthy volunteers:

• Subjects aged = 5 years.
• Free, informed and signed consent of the witness, or if applicable of both parents or legal representatives for minors.
• Patient affiliated to a social security system or similar. Exclusion Criteria:

For patients with Loeys-Dietz syndrome:

• Patient with an evolving or recently healed (< 3 months) cancer that could alter the immunologic profile.
• Patient with an evolving or recently healed (< 3 months) infection that could alter the immunologic profile.
• Patient with a weight of less than 20 kg.
• Pregnant woman.
• Patient participating in another research study with an exclusion period exclusion period still in progress.

For healthy volunteers:

• Subject with an active or recently cured (< 3 months) cancer that could alter the immunologic profile.
• Subject with an active or recently healed (< 3 months) infection that could alter the immunological profile.
• Patient with a weight of less than 20 kg.
• Pregnant woman.
• Subject participating in another research study with an exclusion period exclusion period still in progress.
• Persons under court protection.

Related Conditions & MeSH terms

• Loeys-Dietz Syndrome
• Syndrome

Intervention

Biological:
• blood samples
Only one visit for each participant: A large majority of visits will be part of patients' usual care. Medical examination : weight, gender, blood pressure, medical history Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma
• blood samples
Only one visit for each participant: Medical examination : weight, gender, blood pressure, medical history Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma

Locations

Country	Name	City	State
France	Hôpital Femme-Mère-Enfant / Centre de Compétences pour le syndrome de Marfan et apparentés	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of circulating TFH lymphocyte subpopulation.	Measured from the Blood samples of each patients / volunteers.	Day 1
Secondary	Intracellular pSmad2/3 labeling level of circulating TFH lymphocytes.	Measured from the Blood samples of each patients / volunteers.	Day 1
Secondary	Identification of Immuno-allergic pathologies	Identification of Immuno-allergic, serious infectious pathologies (diagnostic criteria, severity criteria, treatment, current activity) in LDS patients.	Day 1
Secondary	Identification of serious infectious pathologies	Identification of serious infectious pathologies (diagnostic criteria, severity criteria, treatment, current activity) in LDS patients.	Day 1
Secondary	Identification of Vascular complications	Identification of Vascular, morpho-skeletal complications (diagnostic criteria, severity criteria, treatment, current activity) current course) in patients with LDS.	Day 1
Secondary	Identification morpho-skeletal complications	Identification of morpho-skeletal complications (diagnostic criteria, severity criteria, treatment, current activity) current course) in patients with LDS.	Day 1